AR在乳腺癌中的表达和预后及其与ER和PR的关系  

The expression and Prognostic Significanc of androgen receptor in breast cancer and its relationship with estrogen receptor and progesterone receptor

作　　者：袁轶群[1] 郭一川[1] 方宁宁[1] 

机构地区：[1]新疆生产建设兵团第一师医院病理科,新疆阿克苏843000

出　　处：《农垦医学》2016年第2期111-114,共4页Journal of Nongken Medicine

摘　　要：目的:探讨乳腺癌中雄激素受体(androgen receptor,AR)的表达和预后及其与雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)的关系。方法:采用免疫组织化学En Vision法检测AR、ER、PR在155例乳腺癌中的表达,并分析其与乳腺癌临床病理因素的关系及其对预后的影响。结果:AR的阳性率为59.4%。AR的表达与肿瘤大小、组织学分级、淋巴结转移相关(p<0.05);且AR的表达与ER、PR呈正相关。随访显示,AR、ER、PR阴性者的5年总生存率和无瘤生存率均明显低于AR、ER、PR阳性者。结论:AR、ER、PR阳性者较AR、ER、PR阴性者预后好。Objective： To study the expression of androgen receptors in breast cancer,and its relationship between clinicopathological factors and prognosis with estrogen receptor and progesterone receptor.Methods：Immunohistochemical method was used to detect AR、ER and PR in 155 cases of breast cancer,and to analyze its relationship with clinical pathologic factors and prognosis.Results：The positive rate of AR expression was 59.4% in breast cancer.The expression of AR and tumor size,histological grade,Lymph node metastasis（P〈0.05）;the expression of AR and ER,PR were positively correlated.The Follow-up showed that five years overall survival and disease-free survival rates of the patients with the expression of AR, ER and PR negative were significantly lower than those with AR, ER and PR positive.Conclusion：The patients with AR,ER and PR positive have good prognosis than AR,ER and PR negative.

关 键 词：雄激素受体 乳腺癌 预后 

分 类 号：R737.9[医药卫生—肿瘤]